GlassScriptPhysician profile
Joseph L Capasso
NPI 1780733279
$16,582.94
in general payments reported to CMS, 2019-2025
33 companies · $3,576 in 2025
The $3,576 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,185 · 2022: $2,955 · 2023: $3,325 · 2024: $3,542 · 2025: $3,576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,396 · Education: $597 · Consulting Fee: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,395.54 |
| Education | $597.33 |
| Consulting Fee | $450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,397.46 | 2021-2025 | |
| Galderma Laboratories, L.P. | $1,885.68 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Leo Pharma INC. | $1,586.35 | 2021-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $1,499.84 | 2021-2025 | |
| Janssen Biotech, INC. | $1,404.19 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $1,161.36 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $1,026.37 | 2021-2025 | |
| Incyte Corporation | $609.28 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $549.47 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $516.95 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $515.10 | 2021-2025 | Ilumya |
| Dermavant Sciences, INC. | $452.08 | 2023-2024 | Vtama |
| Ucb, INC. | $424.46 | 2021-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $372.46 | 2021-2025 | Cabtreo, Siliq, Arazlo |
| Almirall LLC | $303.37 | 2021-2025 | Seysara |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $277.93 | 2021-2025 | Otezla, Otezla |
| Lilly USA, LLC | $252.72 | 2021-2025 | Taltz, Ebglyss |
| Biocomposites INC | $232.86 | 2021 | |
| Vyne Pharmaceuticals INC. | $188.46 | 2021 | |
| Pfizer INC. | $166.12 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $147.39 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2022 | |
| Kerecis Limited | $97.10 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Organon LLC | $95.17 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.44 | 2023-2025 | Spevigo |
| Journey Medical Corporation | $53.39 | 2022-2025 | |
| Botanix Sb INC | $47.08 | 2025 | Sofdra |
| Paratek Pharmaceuticals, INC. | $35.46 | 2021-2024 | Nuzyra |
| Helsinn Therapeutics (U.S.), INC. | $32.80 | 2021-2023 | Valchlor |
| Kyowa Kirin, INC. | $24.00 | 2024 | Poteligeo |
| Nabriva Therapeutics, Plc | $20.56 | 2022 | |
| Smith+Nephew, INC. | $18.95 | 2024 | Grafix Pl |
| Sebela Pharmaceuticals INC. | $16.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Capasso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.